This Article Full Text Full Text (PDF) All Versions of this Article: 38/8/2213    most recent STROKEAHA.107.494088v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Williams, R. B. Search for Related Content PubMed PubMed Citation Articles by Williams, R. B. Related Collections Primary prevention Secondary prevention Pathophysiology Risk Factors Gene expression Genetics of cardiovascular disease Related Article

(Stroke. 2007;38:2213.)
© 2007 American Heart Association, Inc.

Editorials

Lower Central Nervous System Serotonergic Function and Risk of Cardiovascular Disease

Where Are We, What’s Next?

Redford B. Williams, MD

From the Behavioral Medicine Research Center, Duke University Medical Center, Durham, NC.

Correspondence to Redford B. Williams, Behavioral Medicine Research Center, Box 3926, Duke University Medical Center, Durham, NC 27710. E-mail redfordw@duke.edu

Key Words: etiology • genetics • heart brain relationships • prevention • risk factors

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 2228–2233.

In 1994 I hypothesized that "deficient central nervous system serotonergic function" is a neurobiological substrate that could account for the clustering of psychosocial, biological and behavioral characteristics that increase risk of developing cardiovascular disease.¹ It is gratifying, therefore, to see in this issue of Stroke the report by Muldoon et al² that an established index of reduced central nervous system (CNS) serotonergic function—a smaller prolactin response to intravenous administration of the selective serotonin reuptake inhibitor (SSRI) citalopram—is associated with more severe preclinical atherosclerosis as indexed by carotid artery intima-medial thickness. This finding provides encouraging evidence that dysregulated CNS serotonergic function plays a role in the pathogenesis of cardiovascular disease (CVD). There are 2 questions that must be addressed, however, before this role can be considered as established, the precise mechanisms understood, and the knowledge used to guide the development of improved approaches to the prevention, treatment and rehabilitation of CVD.

First, what determines the individual differences in prolactin response to 5HT reuptake inhibition? One important source of this variability across individuals is variation in genes that regulate 5HT synthesis (tryptophan hydroxylase), release and reuptake (5HT transporter) and metabolism (monoamine oxidase-A), and encode for 5HT receptors that mediate effects of synaptic 5HT on CVD endophenotypes. In their prior work this same group has demonstrated the importance of variation in some of these genes by showing that functional polymorphisms in the 5HT transporter (5HTTLPR) and monoamine oxidase-A (MAOA-uVNTR) genes moderate the prolactin . . . [Full Text of this Article]

Related Article:

Lower Central Serotonergic Responsivity Is Associated With Preclinical Carotid Artery Atherosclerosis

Matthew F. Muldoon, Rachel H. Mackey, Kim Sutton-Tyrrell, Janine D. Flory, Bruce G. Pollock, and Stephen B. Manuck
Stroke 2007 38: 2228-2233. [Abstract] [Full Text] [PDF]